Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Certain human leukemias can be treated by targeting stem-cell microRNAs: Research

Certain human leukemias can be treated by targeting stem-cell microRNAs: Research

Acceleron's ACE-031 protein therapeutic for DMD receives FDA Fast Track designation

Acceleron's ACE-031 protein therapeutic for DMD receives FDA Fast Track designation

International conference to discuss research, unresolved issues of sickle cell disease

International conference to discuss research, unresolved issues of sickle cell disease

Long term decline in hemoglobin may announce onset of colorectal cancer

Long term decline in hemoglobin may announce onset of colorectal cancer

U.S. clinical trials provide further evidence of importance of storing umbilical cord blood

U.S. clinical trials provide further evidence of importance of storing umbilical cord blood

microRNA protects red blood cells from oxidant stress: Study

microRNA protects red blood cells from oxidant stress: Study

Researchers create artificial RNA inhibitor to block excess blood cells formation

Researchers create artificial RNA inhibitor to block excess blood cells formation

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Researchers discover enzyme crucial for DNA repair

Researchers discover enzyme crucial for DNA repair

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

Celgene second-quarter non-GAAP total revenue increases 36% to $850 million

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

New Zealand MEDSAFE approves ABRAXANE for metastatic breast cancer

Intensive chemotherapy may benefit elderly patients with acute myeloid leukemia

Intensive chemotherapy may benefit elderly patients with acute myeloid leukemia

AMAG attributes increased second-quarter revenues of $18.8 million to Feraheme

AMAG attributes increased second-quarter revenues of $18.8 million to Feraheme

HemoBioTech receives patent for HemoTech treatment of acute blood loss

HemoBioTech receives patent for HemoTech treatment of acute blood loss

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos reports net loss of $20.0 million for second-quarter 2010

Allos reports net loss of $20.0 million for second-quarter 2010

Research findings provide new insight into skeletal development

Research findings provide new insight into skeletal development

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Medicare to bundle payments for end-stage renal care, reward quality

Medicare to bundle payments for end-stage renal care, reward quality

Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia

Hospira commences EPO Phase I U.S. clinical trial in renal dysfunction patients with anemia

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.